Skip to main navigation Skip to search Skip to main content

ASHP Guidelines on Pharmacist Involvement in HIV Care

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

    Abstract

    The epidemic of human immunodeficiency virus (HIV) infection in the United States has changed dramatically since its initial recognition in 1981.1 Early in the epidemic, the incidence of HIV reached over 130,000 new cases per year, and death as a result of acquired immunodeficiency syndrome (AIDS) was an almost certain prognosis for those infected.2 Significant advances in the strategies to prevent HIV transmission and in the medical care of patients with HIV infection led to significant reductions in both HIV transmission events and AIDS-related deaths over time. Among these advancements were an understanding of HIV infection pathophysiology, identification of HIV transmission modes, development of public health interventions targeting behavioral changes in high-risk populations, and identification of novel HIV medication targets leading to advances in HIV treatment and eventually combination antiretroviral therapy (ART).

    Original languageAmerican English
    Title of host publicationASHP Best Practices: Position and Guidance Documents of ASHP 2015-2016
    StatePublished - Jan 1 2015

    Keywords

    • HIV care
    • pharmacist involvement
    • pharmacology

    Disciplines

    • Medicine and Health Sciences
    • Pharmacy and Pharmaceutical Sciences

    Fingerprint

    Dive into the research topics of 'ASHP Guidelines on Pharmacist Involvement in HIV Care'. Together they form a unique fingerprint.

    Cite this